JMPWA
GALT icon

JP Morgan Private Wealth Advisors’s Galectin Therapeutics GALT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26,000
Closed -$87K – 1328
2017
Q4 		$87K Hold
26,000
– – ﹤0.01% 1238
2017
Q3 		$56K Hold
26,000
– – ﹤0.01% 1214
2017
Q2 		$64K Hold
26,000
– – ﹤0.01% 1204
2017
Q1 		$60K Hold
26,000
– – ﹤0.01% 1304
2016
Q4 		$25K Hold
26,000
– – ﹤0.01% 1237
2016
Q3 		$29K Hold
26,000
– – ﹤0.01% 1218
2016
Q2 		$38K Buy
+26,000
New +$38.1K ﹤0.01% 1238

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

JP Morgan Private Wealth Advisors's GALT Position: Q1 2018 in Review

JP Morgan Private Wealth Advisors sold out of Galectin Therapeutics (GALT) in Q1 2018, closing a stake of 26,000 shares — an estimated $87K sold.

JP Morgan Private Wealth Advisors first reported a position in GALT in Q2 2016 and held it in 7 quarters. The position peaked at $87K in Q4 2017. 62 funds tracked by Wall St. Rank hold GALT as of Q1 2018.

  • JP Morgan Private Wealth Advisors reported no remaining Galectin Therapeutics position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 26,000 Galectin Therapeutics shares in Q1 2018, an estimated $87K.
  • JP Morgan Private Wealth Advisors first reported a position in Galectin Therapeutics in Q2 2016 and held it in 7 quarters.
  • JP Morgan Private Wealth Advisors's Galectin Therapeutics position peaked at $87K in Q4 2017.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2018.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2018, filed 10 May 2018.